Welcome to our dedicated page for Cytosorbents SEC filings (Ticker: CTSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CytoSorbents Corporation (NASDAQ: CTSO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents include Form 8‑K current reports, which CytoSorbents uses to announce material events such as quarterly financial results, regulatory updates for its DrugSorb™-ATR investigational device, and developments in its interactions with the U.S. Food and Drug Administration and Health Canada.
Through these filings, investors can review how CytoSorbents reports on revenue performance, gross margin trends, credit agreement amendments, and workforce and cost reduction programs, as well as the status of its De Novo applications and appeal processes for DrugSorb‑ATR. The 8‑K reports also confirm key listing information, including that the company’s common stock trades on the Nasdaq Capital Market under the CTSO ticker.
On Stock Titan, each new CytoSorbents filing is captured from EDGAR and presented with AI-powered summaries that explain the main points in clear language. This helps readers quickly understand the significance of items such as regulatory decisions, financing arrangements, or other corporate actions without having to parse every line of the original document.
Users can explore historical filings to follow the evolution of CytoSorbents’ regulatory strategy for its blood purification products, including CytoSorb® and DrugSorb‑ATR, and to see how the company communicates material information to the market over time. The page is designed to make it easier to track CTSO’s official disclosures, from earnings‑related 8‑Ks to other event‑driven reports, with AI insights that highlight what matters most to investors and analysts.
CytoSorbents Corporation received a 180-day extension from Nasdaq, until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for its common stock. The company will regain compliance if its share price closes at or above $1.00 for at least 10 consecutive trading days before that date.
The notice has no immediate effect on the Nasdaq listing or SEC reporting, but the company warns there is no assurance it will regain compliance and its stock could be delisted. CytoSorbents is monitoring its share price and is considering options to address the deficiency, including a possible reverse stock split.
CytoSorbents Corporation focuses on blood purification technologies for critical care and cardiac surgery, built around highly porous polymer bead cartridges used with standard hospital blood pumps. Its flagship CytoSorb device is approved in the European Union and distributed in more than 70 countries, with over 300,000 devices used and cumulative sales of about $285.3 million.
The company is pursuing North American approval of DrugSorb‑ATR to remove antithrombotic drugs during coronary artery bypass graft surgery. A pivotal STAR‑T trial showed safety and reduced perioperative bleeding in urgent CABG patients on ticagrelor, but the FDA denied the initial De Novo request in 2025, asking for more information; CytoSorbents is preparing a new submission after further discussions. Health Canada also refused the initial license, with resubmission planned after U.S. clarity.
CytoSorbents supplements product revenue with about $44.0 million of cumulative non‑dilutive grants for programs like HemoDefend‑BGA and hyperkalemia adsorbers, and records a 3% royalty on specified products, totaling roughly $1.1 million in 2025. As of June 30, 2025, non‑affiliate market value was approximately $60.6 million, with about 62.7 million common shares outstanding as of March 20, 2026.
CytoSorbents Corporation reported modest revenue growth and a sharply reduced loss for 2025. Full-year revenue rose 4% to $37.1 million, with Q4 revenue of $9.2 million. Gross profit increased to $26.5 million, driven by higher sales outside Germany and distributor growth.
The net loss narrowed to $8.2 million from $20.7 million in 2024, helped by lower research and development spending and a favorable foreign currency impact. The company ended 2025 with $6.2 million in cash and cash equivalents and total stockholders’ equity of $5.9 million, while long-term debt rose to $16.7 million. Management implemented a 10% headcount reduction and other cost measures and now anticipates achieving cash flow breakeven in the second half of 2026, while continuing to pursue FDA De Novo authorization for DrugSorb-ATR.
Avenir Corporation and James H. Rooney report significant ownership in Cytosorbents Corp. They disclose beneficial ownership of 5,230,099 shares of Cytosorbents common stock, representing about 8.3% of the outstanding class.
The filing states they share voting and dispositive power over these shares. Avenir is described as a Virginia-based investment adviser, and Rooney is its portfolio manager and shareholder. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Cytosorbents.
Cytosorbents Corp (CTSO) reported that its Chief Executive Officer and director, Phillip P. Chan, acquired additional company stock in an open market transaction. On 11/18/2025, he purchased 100,000 shares of Common Stock at a price of $0.64 per share. Following this transaction, he beneficially owns 1,482,963 shares, reflecting both directly owned shares and various restricted stock units (RSUs).
The footnotes explain that his holdings include multiple RSU grants that either vest upon a "Change In Control" under the company’s 2014 Long-Term Incentive Plan or in equal parts on the first and second anniversaries of their grant dates, subject to continued service. His position also includes 1,113,363 shares of Common Stock owned outright.
CytoSorbents Corporation announced that it issued a press release with financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 under Item 2.02.
The company states this information is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings except as specifically stated.
CytoSorbents Corporation furnished a current report stating that it issued a press release providing a regulatory update on its -ATR program. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities law.
CytoSorbents Corporation filed a current report describing a regulatory update for its DrugSorbTM-ATR device. The company states that it issued a press release announcing the outcome of its appeal to the U.S. Food and Drug Administration regarding the FDA’s earlier denial of its De Novo Market Authorization request for DrugSorb-ATR.
The press release with details of the appeal outcome is furnished as Exhibit 99.1 to the report, rather than being summarized in the body of the filing. This filing mainly serves to formally notify investors that the FDA appeal outcome and related information are now available through that exhibit.
Cytosorbents Corp. (CTSO) filed a Form 144 reporting a proposed sale of 10,548 common shares through Fidelity Brokerage Services with an approximate sale date of 08/19/2025. The filing shows the shares were acquired on 08/14/2025 by restricted stock vesting from the issuer as compensation. The aggregate market value of the planned sale is listed as $11,447.74 and the company reports 62,761,805 shares outstanding. No other sales in the past three months are reported.
Phillip P. Chan, Chief Executive Officer and director of Cytosorbents Corp (CTSO), reported equity awards and holdings on 08/08/2025. The filing shows an acquisition of 105,600 restricted stock units (RSUs) with a reported price of $0 and a grant of 136,400 stock options with a $1 exercise price and an expiration date of 08/08/2035. Following the reported transactions, the filing reports 1,382,963 shares of common stock beneficially owned. Footnotes disclose multiple prior RSU grants (2015–2024), including 48,000 unvested RSUs from April 2, 2024, and state that 1,013,363 shares are owned outright by the reporting person. The RSUs and options vest in scheduled tranches and vesting generally requires continued service.